Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free GCAN Stock Alerts

Greater Cannabis (GCAN) Competitors

Greater Cannabis logo
$0.38 +0.01 (+2.57%)
As of 09/9/2026 11:58 AM Eastern
Compare

GCAN vs. SXTPW, BFRIW, CINGW, CLVR, and CMRAW

Should you buy Greater Cannabis stock or one of its competitors? Greater Cannabis's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Cingulate (CINGW), Clever Leaves (CLVR), and Comera Life Sciences (CMRAW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Greater Cannabis compare to 60 Degrees Pharmaceuticals?

Greater Cannabis (NASDAQ:GCAN) and 60 Degrees Pharmaceuticals (NASDAQ:SXTPW) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Greater Cannabis. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Greater Cannabis. 60 Degrees Pharmaceuticals' average media sentiment score of 0.96 beat Greater Cannabis' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Greater Cannabis Neutral
60 Degrees Pharmaceuticals Positive

Company Net Margins Return on Equity Return on Assets
Greater CannabisN/A N/A N/A
60 Degrees Pharmaceuticals N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Greater CannabisN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A

Summary

60 Degrees Pharmaceuticals beats Greater Cannabis on 3 of the 3 factors compared between the two stocks.

How does Greater Cannabis compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Greater Cannabis (NASDAQ:GCAN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Greater Cannabis N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$46.18MN/AN/AN/AN/A
Greater CannabisN/AN/AN/AN/AN/A

In the previous week, Biofrontera had 2 more articles in the media than Greater Cannabis. MarketBeat recorded 2 mentions for Biofrontera and 0 mentions for Greater Cannabis. Biofrontera's average media sentiment score of 0.44 beat Greater Cannabis' score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company Overall Sentiment
Biofrontera Neutral
Greater Cannabis Neutral

Summary

Biofrontera beats Greater Cannabis on 3 of the 3 factors compared between the two stocks.

How does Greater Cannabis compare to Cingulate?

Cingulate (NASDAQ:CINGW) and Greater Cannabis (NASDAQ:GCAN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

In the previous week, Cingulate had 2 more articles in the media than Greater Cannabis. MarketBeat recorded 2 mentions for Cingulate and 0 mentions for Greater Cannabis. Cingulate's average media sentiment score of 1.43 beat Greater Cannabis' score of 0.00 indicating that Cingulate is being referred to more favorably in the media.

Company Overall Sentiment
Cingulate Positive
Greater Cannabis Neutral

Company Net Margins Return on Equity Return on Assets
CingulateN/A N/A N/A
Greater Cannabis N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/AN/AN/AN/A
Greater CannabisN/AN/AN/AN/AN/A

Summary

Cingulate beats Greater Cannabis on 2 of the 2 factors compared between the two stocks.

How does Greater Cannabis compare to Clever Leaves?

Clever Leaves (NASDAQ:CLVR) and Greater Cannabis (NASDAQ:GCAN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Greater Cannabis has lower revenue, but higher earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A
Greater CannabisN/AN/AN/AN/AN/A

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Greater Cannabis'average media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Greater Cannabis Neutral

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Greater Cannabis N/A N/A N/A

Summary

Clever Leaves beats Greater Cannabis on 3 of the 3 factors compared between the two stocks.

How does Greater Cannabis compare to Comera Life Sciences?

Greater Cannabis (NASDAQ:GCAN) and Comera Life Sciences (NASDAQ:CMRAW) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

In the previous week, Greater Cannabis' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Greater Cannabis Neutral
Comera Life Sciences Neutral

Company Net Margins Return on Equity Return on Assets
Greater CannabisN/A N/A N/A
Comera Life Sciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Greater CannabisN/AN/AN/AN/AN/A
Comera Life Sciences$1.00MN/AN/AN/AN/A

Summary

Comera Life Sciences beats Greater Cannabis on 1 of the 1 factors compared between the two stocks.

Get Greater Cannabis News Delivered to You Automatically

Sign up to receive the latest news and ratings for GCAN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GCAN vs. The Competition

Export
MetricGreater CannabisPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$12.46B$7.21B$12.81B
Dividend YieldN/A2.62%2.56%10.55%
P/E RatioN/A797.19272.8425.11
Price / SalesN/A756.23625.4190.53
Price / CashN/A90.5577.3351.83
Price / BookN/A10.4310.416.18
Net IncomeN/A$2.82B$3.49B$358.18M
7 Day Performance65.00%-3.23%-3.16%-2.51%
1 Month Performance35.54%2.85%0.02%-2.73%
1 Year PerformanceN/A3.11%17.33%7.73%

Greater Cannabis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GCAN
Greater Cannabis
N/A$0.38
+2.6%		N/A+126,400.0%$0.00N/AN/A1
SXTPW
60 Degrees Pharmaceuticals
N/A$0.03
-15.5%		N/A-47.5%$0.00$1.11MN/A2
BFRIW
Biofrontera
N/A$0.03
flat		N/A-81.2%$0.00$46.18MN/A70
CINGW
Cingulate
N/A$0.01
-4.2%		N/A-85.7%$0.00N/AN/A20
CLVR
Clever Leaves
N/A$0.00
flat		N/AN/A$0.00$17.42MN/A560

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GCAN) was last updated on 9/11/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel